Clinical trials: Intravenous Infusions
Peritoneal Dialysis-associated Peritonitis, Peritoneal Dialysis (PD)
Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis
This study aims to investigate the pharmacokinetics (PK) and pharmacodynamic (PD) profiles of four commonly used antibiotics - meropenem, ampicillin, aztreonam, and ciprofloxacin - administered via intravenous (i.v.) and…
- Conditions
- Peritoneal Dialysis-associated Peritonitis, Peritoneal Dialysis (PD), Pharmacokinetics, Intravenous Administration
- Trial name
- NCT07113587
- Testing
- Application of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis, Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis, Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis
- Where
- Austria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Karl Landsteiner Insitute for Nephrology and Haemato-Oncology
Pain
Antagonistic Interaction CB1-paracetamol
Evaluation of an possible inhibiting effect of Rimonabant on the analgesic effect of Paracetamol in healthy volunteers
- Trial name
- NCT00750347
- Where
- 2 sites in France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
HIV Infections
Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers
To evaluate how the drug dextran sulfate (DS) is absorbed by the stomach and intestines when taken by mouth. To evaluate its effect on blood coagulation. DS has been reported to have anti-HIV activity.
- Trial name
- NCT00000690
- Testing
- Dextran sulfate
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Graft Rejection After Organ Transplantation
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects
This is a single-center, double-blind, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-3032 in healthy adults.
- Trial name
- NCT06090799
- Testing
- SHR-3032
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Renal Impairment
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100
- Trial name
- NCT05086107
- Testing
- BV100
- Where
- Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- BioVersys AG
Healthy
Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself
This trial will consist of two parts: A pilot study in a three-way cross over trial to determine the highest well tolerated dose of Ritodrine (Pre-Par®), the impact of Atosiban (Tractocile®) on the hemodynamics and hence the…
- Trial name
- NCT00679705
- Testing
- Ritodrine, Atosiban
- Where
- Belgium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Healthy
Single Dose Study of PF-05230907 in Healthy Japanese Subjects
The purpose of this study is the following: To determine the safety and tolerability of single ascending intravenous (IV) doses of PF-05230907 in healthy Japanese subjects.
- Trial name
- NCT02537002
- Testing
- PF-05230907
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers
To compare with placebo the anticoagulant activity of three dosages of BIBT 986 on parameters of coagulation, platelet activation and inflammation in a model of tissue factor triggered activation of the coagulation system; to…
- Trial name
- NCT02259881
- Testing
- Low dose of BIBT 986 CL, per i.v. infusion, Medium dose of BIBT 986 CL, per i.v. infusion, High dose of BIBT 986 CL, per i.v. infusion
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
SARS-CoV-2 Infection
SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion
This is the first-in-human phase 1/2a trial of the intravenous administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals.
- Trial name
- NCT04631666
- Testing
- DZIF-10c
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Thrombosis
A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV infusions of BMS-962212 in healthy subjects…
- Trial name
- NCT03197779
- Testing
- BMS-962212, Aspirin
- Where
- 3 sites in United States
- Volunteers
- 691 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pharmacokinetics of ASP2408, Healthy Subjects
A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) after intravenous (IV) administration of ASP2408 manufactured from a new production clone and also following single ascending doses of…
- Trial name
- NCT02150070
- Testing
- ASP2408
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.